| Inventor | Institute |
|---|---|
| Irene Leigh | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| SKU: | 153429 |
|---|---|
| Product description: | Keratin 19 was first detected in squamous cell carcinoma lines and it is identifiable by its characteristically low molecular weight on SDS gels at 40 kD. It is generally regarded as being characteristic of simple epithelia such as intestine, kidney collecting ducts, gallbladder, mesothelium, and glandular secretory cells. Keratin 19 has unusually wide tissue distribution, and has been reported to be present, in significant quantities and under apparently normal conditions, in both stratified and squamous epithelia. Keratin 19 is a tumour marker used to establish poor prognosis in several types of carcinoma including hepatocellular and NSCL. |
| Alternate name: | 4 kDa keratin intermediate filament antibody, CK 19 antibody, CK-19 antibody, CK19 antibody, Cytokeratin 19 antibody, Cytokeratin-19 antibody, K19 antibody, K1C19_HUMAN antibody, K1CS antibody, Keratin 19 antibody, Keratin type I 4 kD antibody, Keratin type I 4kD antibody, Keratin type I cytoskeletal, 19 antibody, Keratin, type I cytoskeletal 19 antibody, Keratin type I 4 kd antibody, Keratin-19 antibody, KRT19 antibody, MGC15366 antibody |
| Conjugation: | Unconjugated |
| Molecular weight: | 40 kDa |
| Immunogen: | Sonicated cytoskeleton fractions (material insoluble in 1% Nonidet-P40(N-P40)) from SVK14 cells (SV40-transformed human neonatalkeratinocytes: 19) |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 153429 |
|---|---|
| Provenance and Ownership: | The Anti-Keratin 19 [LP2K] is owned by Cancer Research UK. CancerTools supplies the Anti-Keratin 19 [LP2K] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Keratin 19 [LP2K] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer; Cell biology |
| Application: | IHC ; WB |
| Target: | Keratin 19 |
| Reactivity: | Human |
| Clone: | LP2K |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Keratin 19 was first detected in squamous cell carcinoma lines and it is identifiable by its characteristically low molecular weight on SDS gels at 40 kD. It is generally regarded as being characteristic of simple epithelia such as intestine, kidney collecting ducts, gallbladder, mesothelium, and glandular secretory cells. Keratin 19 has unusually wide tissue distribution, and has been reported to be present, in significant quantities and under apparently normal conditions, in both stratified and squamous epithelia. Keratin 19 is a tumour marker used to establish poor prognosis in several types of carcinoma including hepatocellular and NSCL. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Bttger et al. 1995. Eur J Biochem. 231(2):475-85. PMID: 7543411. Epitope mapping of monoclonal antibodies to keratin 19 using keratin fragments, synthetic peptides and phage peptide libraries. Fridmacher et al. 1992. Development. 115(2):503-17. PMID: 1385062. Differential expression of acidic cytokeratins 18 and 19 during sexual differentiation of the rat gonad. Stasiak et al. 1989. J Invest Dermatol. 92(5):707-16. PMID: 2469734. Keratin 19: predicted amino acid sequence and broad tissue distribution suggest it evolved from keratinocyte keratins. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.